Cordlife
Cordlife is a Singapore-based consumer health company specializing in cord blood and cord lining banking, with related maternal and child diagnostic services across Asia.
Last updated August 31, 2026
AI crawler reads
5requests
1companies- Anthropic5
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Cordlife is the consumer-facing brand of Cordlife Group Limited, a Singapore-incorporated healthcare company focused on the collection, processing and long-term cryogenic storage of cord blood and umbilical cord lining. The company was incorporated in May 2001 and developed a regional network of private stem-cell banking facilities serving families in Singapore and other Asian markets. Its business model combines birth-related biological-material banking with diagnostic services aimed primarily at mothers, newborns and children. The company's principal offering is private cord blood banking. Cord blood collected after birth contains hematopoietic stem cells that may be used in certain transplant procedures, subject to medical suitability and regulatory requirements. Cordlife also expanded into cord lining banking, seeking to preserve tissue from the umbilical cord as a potential source of mesenchymal and epithelial stem cells. These services are generally marketed to expectant parents as long-term biological-resource preservation products rather than as conventional medical insurance. Cordlife's diagnostic portfolio has included newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening. Metascreen, its newborn metabolic screening service, was introduced in India in 2013 and subsequently offered in other markets. Non-invasive prenatal testing analyzes fetal DNA circulating in maternal blood to screen for chromosomal conditions, while the Eyescreen service uses photoscreening technology to identify possible childhood vision problems, including strabismus and amblyopia. The group expanded through subsidiaries, partnerships and acquisitions. It entered Hong Kong and mainland China-related markets in the mid-2000s, built or operated facilities in Indonesia, India and the Philippines, and later acquired a majority interest in Malaysia's StemLife. The company has described its network as one of the largest private cord blood banking networks in Asia. Facilities historically operated in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia, with services marketed in additional Southeast Asian and South Asian countries. Cordlife Group was listed on the Mainboard of the Singapore Exchange in March 2012. Before 2023, the company emphasized laboratory accreditation, quality systems and transplant-related experience. Its facilities had historically held accreditation from organizations including AABB and, in selected markets, FACT-NETCORD or the College of American Pathologists. The reference material records that AABB accreditation for the group's facilities was withdrawn in 2024. The company entered a major regulatory and reputational crisis in late 2023. Singapore's Ministry of Health reported that cryopreserved cord blood units had been exposed to temperatures outside the required range. At least 2,150 client units were reported to have been damaged and rendered unsuitable for stem-cell transplantation. Singapore subsequently suspended Cordlife's ability to collect, test, process or store new cord blood and human tissues. The suspension was later extended while the company worked on validation and remediation measures. In 2024, the former chief executive and several board members were reported to have been arrested and released on bail, and the company was allowed to resume some services on a limited basis in August. The incident remains central to the brand's current identity, governance scrutiny and regulatory standing.
History
Cordlife Pte Ltd was incorporated in Singapore on 2 May 2001 and subsequently obtained authorization to operate as a private cord blood bank. In 2003 it merged with Cytomatrix LLC. Its corporate history was initially connected with CyGenics Limited, whose holding company was listed on the Australian Securities Exchange in 2004. The business expanded into Hong Kong and mainland China-related markets in 2005 through Cordlife Hong Kong. In 2007, CyGenics was renamed Cordlife Limited, while Cordlife Hong Kong obtained ISO 9001 certification. During the late 2000s and early 2010s, Cordlife developed a regional operating model. It opened or expanded facilities in Singapore, Indonesia, India and the Philippines, and entered into arrangements concerning businesses in those markets. Cordlife reported clinical milestones involving the release of stored cord blood units for treatment or transplantation, including cases involving cerebral palsy, neuroblastoma and a mixed stem-cell transplant in India. The company also invested in a Guangdong cord blood banking business and transferred relevant interests into the group structure. A demerger from Cordlife Limited took place in 2011, accompanied by rights-of-first-refusal arrangements concerning operations in Indonesia, the Philippines and India. Cordlife Group Limited then listed on the Mainboard of the Singapore Exchange on 29 March 2012. In 2013, the Singapore business moved into a company-owned office and laboratory facility at A'Posh Bizhub in Yishun. That year, the Indian subsidiary launched Metascreen, a non-invasive newborn metabolic screening service. The company broadened its service portfolio and regional footprint during the middle of the 2010s. It introduced or expanded cord lining banking and prenatal and newborn screening services, while its facilities pursued external quality accreditation. Cordlife received industry recognition including a Frost & Sullivan Singapore Stem Cell Company of the Year award in 2015 and inclusion in Forbes' Asia 200 Best Under a Billion list in the same year. In 2015, the group also became the majority owner of Malaysia's StemLife. Cordlife Singapore obtained FACT-NETCORD accreditation in 2016, and Cordlife India and the Hong Kong Screening Centre obtained College of American Pathologists accreditation that year. In 2018, the group acquired HealthBaby Biotech in Hong Kong. Leadership changed in 2019 when Group Chief Executive Officer Michael Weiss resigned and Tan Poh Lan became chief executive. The business continued to operate as a regional private cord blood and family diagnostics provider, with facilities historically accredited by AABB and other quality organizations. The company's trajectory changed sharply in November 2023, when Singapore's Ministry of Health disclosed that Cordlife had exposed cryopreserved cord blood units to unsuitable temperatures. At least 2,150 client units were affected and reported to be unsuitable for stem-cell transplantation. On 15 December 2023, Singapore imposed a six-month suspension covering the collection, testing, processing and storage of new cord blood and human tissues. The suspension was extended while Cordlife validated a revised processing method. The crisis also led to investigations, arrests and heightened scrutiny of the company's governance, incident reporting and operational controls. The reference material states that AABB accreditation for the group's facilities was withdrawn in 2024. Cordlife was permitted to resume some services on a limited basis in August 2024, but the episode left the company subject to continuing regulatory oversight and materially reshaped its public reputation.
- 2024
Limited resumption of services
[1]Cordlife was permitted to resume selected services on a limited basis after regulatory review.
- 2023
Cord blood storage incident disclosed
[1]Singapore's Ministry of Health disclosed that at least 2,150 stored cord blood units had been damaged by exposure to suboptimal temperatures.
- 2018
HealthBaby acquisition
[1]Cordlife acquired HealthBaby Biotech in Hong Kong, strengthening its private cord blood banking presence there.
- 2015
StemLife becomes a majority-owned subsidiary
[1]Cordlife acquired a majority interest in Malaysian stem-cell banking and therapeutics company StemLife.
- 2013
Metascreen introduced in India
[1]Cordlife India launched its newborn metabolic screening service, Metascreen.
- 2012
Singapore Exchange listing
[1]Cordlife Group Limited listed on the Mainboard of the Singapore Exchange on 29 March 2012.
- 2005
Entry into Hong Kong and mainland China-related markets
[1]Cordlife Hong Kong was established as part of the group's regional expansion.
- 2003
Merger with Cytomatrix
[1]Cordlife merged with Cytomatrix LLC as it developed its corporate and operating structure.
- 2001
Singapore incorporation
[1]Cordlife Pte Ltd was incorporated in Singapore on 2 May 2001.
Products and positioning
A regional private stem-cell banking and family diagnostics provider positioned around biological-material preservation, pregnancy screening and child-health services.
Stem-cell banking
Cord blood banking
Cordlife collects, processes and cryogenically stores umbilical cord blood collected after birth. The service is marketed to families seeking to preserve hematopoietic stem cells for possible future medical use. Cord blood units may be released for transplantation only when clinically suitable and in accordance with applicable regulatory and medical requirements.
Tissue banking · 2013
Cord lining banking
Cord lining banking preserves tissue from the umbilical cord for potential future use in cellular therapies and research. Cordlife has promoted technologies intended to recover mesenchymal and epithelial stem-cell populations from cord lining, although availability and regulatory status vary by market.
Newborn diagnostics · 2013
Metascreen
Metascreen is Cordlife's newborn metabolic screening service. It is designed to screen for selected inherited metabolic conditions using a non-invasive testing approach and has been offered in markets including India, Hong Kong, the Philippines, Indonesia and Malaysia.
Prenatal diagnostics
Non-invasive prenatal testing
Cordlife's non-invasive prenatal testing service analyzes fetal DNA in maternal blood to screen for possible chromosomal abnormalities, including conditions commonly associated with Down syndrome, Edwards syndrome and Patau syndrome. It has been offered in Singapore, India, Indonesia and the Philippines.
Paediatric vision screening
Eyescreen
Eyescreen is a paediatric vision screening service marketed by Cordlife Technologies in Singapore. Using photoscreening technology, it is intended for children approximately six months to six years old and can identify risk indicators for conditions such as strabismus and amblyopia.
Controversies
2023
Cryogenic storage temperature incident
Singapore's Ministry of Health reported that Cordlife had exposed cryopreserved cord blood units to suboptimal temperatures. At least 2,150 client units were reported damaged and unsuitable for stem-cell transplantation, triggering a suspension of new cord blood and human tissue activities and extensive regulatory scrutiny.
Brand decisions
2023
Suspend new cord blood and tissue activitiesOtherBackground
Regulators identified temperature-control failures affecting stored cord blood units.
Action taken
Singapore authorities suspended Cordlife's collection, testing, processing and storage of new cord blood and human tissues.
Aftermath
The suspension was extended while the company undertook validation and remediation work, and later resumed selected services on a limited basis.
2012
List the group on the Singapore ExchangeStrategyBackground
Cordlife had developed a regional network of private cord blood banking and diagnostic operations.
Action taken
Cordlife Group Limited listed on the Mainboard of the Singapore Exchange on 29 March 2012.
Aftermath
The listing established the Singapore group as a publicly traded regional healthcare company.
Recent events
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/cordlife · Editorial policy · How profiles are compiled